Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors

Autor: Rammurti T. Kamble, Anita D'Souza, Leslie Lehmann, Kirk R. Schultz, Miguel Angel Diaz, Nandita Khera, Anita J. Kumar, Karen K. Ballen, Siddhartha Ganguly, Yachiyo Kuwatsuka, Wael Saber, Susana R. Marino, Sachiko Seo, Ruta Brazauskas, Baldeep Wirk, Shahrukh K. Hashmi, Christopher Bredeson, Yoshihiro Inamoto, Khalid Bo-Subait, Jean A. Yared, Gregory A. Hale, Navneet S. Majhail, Akshay Sharma, Harry C. Schouten, Saurabh Chhabra, Cesar O. Freytes, Jason Tay, Christopher E. Dandoy, Kehinde Adekola, Bronwen E. Shaw, Stefan O. Ciurea, David Gómez Almaguer, Hasan Hashem, Amir Steinberg, Hemant S. Murthy, Raquel M. Schears, Ayami Yoshimi, Linda J. Burns, David Szwajcer, David I. Marks, Tami John, Richard F. Olsson, Charles F. LeMaistre, William A. Wood, Jan Cerny, Susan K. Parsons, David Buchbinder, Usama Gergis, Nosha Farhadfar, Theresa Hahn, Mahmoud Aljurf, Hélène Schoemans, Sherif M. Badawy, Bipin N. Savani, Sara Beattie, Hillard M. Lazarus
Přispěvatelé: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), Interne Geneeskunde
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Biol Blood Marrow Transplant
Biology of Blood and Marrow Transplantation, 26(3), 553-561. Elsevier Science
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2019.11.003
Popis: Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects. ispartof: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION vol:26 issue:3 pages:553-561 ispartof: location:United States status: published
Databáze: OpenAIRE